invobenitug (procizumab)
Cardiogenic Shock (patients with elevated cDPP3)
Phase 1b/2aActive - Dose Finding
Key Facts
Indication
Cardiogenic Shock (patients with elevated cDPP3)
Phase
Phase 1b/2a
Status
Active - Dose Finding
Company
About 4TEEN4 Pharmaceuticals
4TEEN4 Pharmaceuticals is a clinical-stage biotech company pioneering a novel, pathophysiology-driven approach to treating shock, a critical condition with mortality rates exceeding 40% and no adequate causal therapy. Built on the groundbreaking discovery of circulating Dipeptidyl Peptidase 3 (cDPP3) as a key driver and biomarker, the company is developing invobenitug (procizumab) to neutralize cDPP3 and restore cardiovascular stability. With an experienced leadership team and a biomarker-enriched clinical strategy, 4TEEN4 aims to significantly improve survival for critically ill patients in the ICU.
View full company profile